Navigation Links
Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
Date:3/13/2009

in Peripheral T-Cell Lymphomas Overexpressing Activated Syk" suggested that Syk may play a critical role in some PTCLs and represents a feasible therapeutic target for further clinical study.

Phase 2 Design

The Phase 2 trial will be conducted in two stages at several centers in North America with each patient receiving 200mg of R788 twice a day for a minimum of 8 weeks, or until disease progression or withdrawal from the trial. During stage one, 19 men and women with PTCL who have previously failed to respond to standard of care treatment for their disease are expected to be evaluated. Stage two is expected to include the enrollment of approximately 36 patients. Efficacy will be assessed by CT/PET scans at baseline and CT scans of the disease-involved areas at 8 weeks. Safety will be assessed by periodic physical exams, blood tests and clinical laboratory work, among others. Results of the clinical trial are expected in the second half of 2010.

In June 2008, Rigel first reported results of a Phase 2 clinical trial of R788 in the treatment of patients with relapsed or refractory B-cell non-Hodgkin's lymphomas. R788 was well-tolerated in this patient population and showed therapeutic benefit in patients suffering from certain subcategories of the disease, especially small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) and diffuse large B-cell lymphoma. More details about the outcome of that clinical trial and the role that Syk inhibition may play in the treatment of lymphoma patients can be found at Rigel's website, http://www.rigel.com/rigel/lymphoma.

About Rigel

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intrace
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
2. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
3. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
4. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
7. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
8. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
9. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
10. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
11. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015 ReportsnReports.com adds Global ... 2020 forecasts as well as Global Medical Simulation ... intelligence collection of its library. Complete ... forecasts spread across 164 pages, talking about 7 ... figures is now available at http://www.reportsnreports.com/reports/407046-global-medical-simulation-industry-report-2015.html ...
(Date:8/3/2015)... , Aug. 3, 2015 Par Pharmaceutical Companies, ... call on Friday, August 7, 2015 at 9:00 a.m. ... second quarter ended June 30, 2015.  Par is privately ... the public in its filings with the Securities and ... on its website by following the instructions at ...
(Date:8/3/2015)... OmniSeq, LLC today announced the addition ... SM Genomic Network.  Recently, OmniSeq officially spun ... announced it was making available a suite of ... to genomic diagnostics that provides actionable results to ... rapidly expanding, multidisciplinary cancer care center that is ...
Breaking Medicine Technology:Medical Simulation Market to see 14% CAGR to 2019 2Medical Simulation Market to see 14% CAGR to 2019 3Medical Simulation Market to see 14% CAGR to 2019 4Medical Simulation Market to see 14% CAGR to 2019 5Medical Simulation Market to see 14% CAGR to 2019 6OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3
... New England Journal of Medicine employs Quest Diagnostics, blood-based ... of blood specimens may detect abnormal white blood cells ... leukemia (CLL) develops, according to research published in the ... Journal of Medicine . The finding may lead to ...
... Pharmacyclics (Nasdaq: PCYC ) announced today ... investment by the principals of Pacific Biopharma Group, Ltd. ... Province, People,s Republic of China. The transaction was structured ... Pharmacyclics at $0.93/share. Robert Duggan, CEO of Pharmacyclics ...
Cached Medicine Technology:Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 2Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 3Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 4Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd. 2Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd. 3
(Date:8/3/2015)... , ... August 03, 2015 , ... sweetFrog Enterprises, LLC. ... location is the 20th sweetFrog store operating in the Lone Star State. The premium ... growing companies in 2014. , The store, located at 2916 US-75, Sherman, TX 38652, ...
(Date:8/3/2015)... ... August 03, 2015 , ... Representatives with Health Food Grocers ... , “Our ‘Ask a Nutritionist’ feature on our website is a free service to ... Brisk, nutritionist and spokeswoman for Health Food Grocers. , Health Food Grocers’ website offers ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Since 1978, the ... declined, according to a new publication released today by the AAMC (Association of American ... college graduates over the past three decades, the number of black male applicants to ...
(Date:8/3/2015)... ... August 03, 2015 , ... Code , an industry leader of image-based ... Bluetooth Code Reader accessory that enables a wireless connection between the CR5000 ... a variety of barcode reading applications with iPads, Galaxy Tabs, and many other products ...
(Date:8/3/2015)... Va. (PRWEB) , ... August 03, 2015 , ... The ... the use of health IT to create efficiencies in healthcare information exchange, announced the ... letters to the Health and Human Services (HHS) Secretary, WEDI shared survey results ...
Breaking Medicine News(10 mins):Health News:sweetFrog Reopens Texas Store Today 2Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 2Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4Health News:Code Launches the T500, an Innovative Code Reader Accessory 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4
... manufactured by Merck & Co would result in an increased ... taking the drug. // Statistics show that about 60 patients ... six to 13 days after they first started taking Vioxx. ... Journal. It was contrary to what Merck had previously told ...
... of the Food and Drug Administration has been subjected ... // ,Attorney Barbara Van Gelder has mentioned ... of Lester Crawford. She is believed to have ... Thursday, that she would instruct him to invoke his ...
... and polio immunization campaign commenced with a bit of ... with their children to avail immunization, // and this ... Infact, the stock of vaccines started getting depleted by ... of the vaccination drive. ,Assistant Minister for Medical ...
... hypothermia to help patients with severe heart disease or ... Dalton Dietrich and his colleagues noticed// that the rats ... stroke, but had different responses. ,"We ... temperatures in the rats' brains they found that rates ...
... University Medical School in Melbourne, Australia, it was found ... than a very low-calorie diet.// The surgical procedure consists ... stomach to create a feeling of fullness in patients ... those who have serious medical conditions, such as type ...
... A study conducted by a Brown Medical School professor ... say that postpartum depression is linked to fussy babies.//, ... clinical professor of paediatrics at Brown Medical School and ... Other members include Rhode Island Department of Health's Division ...
Cached Medicine News:
... From simple techniques such as submarine electrophoresis ... Step IEF, the Series 90 Programmable Power ... Series 90 Programmable Power Supplies are available ... or 6000V., All models operate in constant ...
... - 200: 200V, .01-2A. 300: 300V, 4-400mA. ... Select constant voltage or constant current ... gels. - Compact, lightweight and stackable. - ... - Ideal for DNA, RNA and protein ...
... The MAX POWER Programmable Power Supply ... which can handle virtually any application ... current blotting. It is unique in ... The MAX POWER Programmable Power Supply ...
... The e-power series power ... any horizontal gel electrophoresis system. ... constructed to the most rigorous ... recognition as the most compact ...
Medicine Products: